MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Metrics to compare | MIRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMIRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −2.6x | −0.5x | |
PEG Ratio | 0.05 | −0.01 | 0.00 | |
Price/Book | 5.7x | 0.6x | 2.6x | |
Price / LTM Sales | - | 3.1x | 3.0x | |
Upside (Analyst Target) | - | 293.6% | 55.6% | |
Fair Value Upside | Unlock | 3.0% | 10.1% | Unlock |